Kategorija: Moksliniai tyrimai

"Sage Therapeutics" 2 fazės tyrimas sustiprina Huntingtono ligos poveikį pažintinėms funkcijoms

Earlier this week Sage Therapeutics announced the results of their SURVEYOR study which quantified the cognitive impact of Huntington’s Disease.  Using the HD-Cognitive Assessment Battery (HD-CAB) they measured the difference […]

FDA suteikia "uniQure" regeneracinės medicinos pažangiosios terapijos (RMAT) vardą

Today we are very happy in the Huntington community.  The announcement from Uniqure that the company has received the Regenerative Medicine Advanced Therapy (RMAT) “Designation for Investigational Gene Therapy AMT-130 […]

"SOM Biotech" baigia atranką į IIb fazės tyrimą dėl Hantingtono ligos chorea gydymo

"SOM Biotech", klinikinės stadijos vaistų atradimo ir kūrimo bendrovė, kurios veikla grindžiama unikalia patentuota dirbtinio intelekto platforma (SOMAIPRO®), džiaugiasi galėdama pranešti, kad į IIb fazės klinikinę [...]

"Prilenia" planuoja pateikti paraišką dėl leidimo prekiauti pridopidinu Huntingtono ligos gydymui ES

Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael […]

Proveržis - nauja viltis HD pacientams

Scientists from the Weizmann Institute in Israel have published the results of an animal study which holds tremendous promise for the treatment of Huntington’s Disease.  They have discovered that two […]

"uniQure" praneša apie atnaujintus I/II fazės klinikinius AMT-130 genų terapijos, skirtos Huntingtono ligai gydyti, tyrimus

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean […]

"PTC Therapeutics" dalijasi teigiamais tarpiniais duomenimis iš klinikinio tyrimo PIVOT-HD su Huntingtono liga sergančiais pacientais

June 21, 2023 PDF Version – Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks –– Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes –  – Conference […]

"uniQure" skelbia atnaujintą informaciją apie JAV atliekamą I/II fazės klinikinį AMT-130 genų terapijos, skirtos Huntingtono ligai gydyti, tyrimą

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history […]

PRILENIA SKELBIA "PROOF-HD" TYRIMO REZULTATUS: DAUG ŽADANTYS, BET NEVIENAREIKŠMIAI REZULTATAI!

Today, April 25th, Prilenia announced results from the PROOF-HD clinical trial for Huntington’s Disease. Some of the participants showed significant benefits from the Pridopidine drug, while others did not benefit at all.  This […]

"Prilenia" pasiekė paskutinį paciento apsilankymą 3 etapo PROOF-HD klinikiniame tyrime dėl Huntingtono ligos

PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass., 28 March 2023 – Prilenia Therapeutics B.V., a […]